Projects per year
Personal profile
Education
- 2012 PhD, Institute of Clinical Medicine, National Cheng Kung University
Experience
- 2024.8- Distinguished Professor, National Cheng Kung University (NCKU)
- 2023.8- Director, Institute of Clinical Medicine, NCKU
- 2023.8- Director, Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2021.8- Professor, Institute of Clinical Medicine, NCKU
- 2021.8- Joint Appointment Professor, Departments of Oncology & Internal Medicine, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2020.10- Attending Physician, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2020.8-2023.7 Deputy Director, Cancer Center, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2017.8-2021.7 Associate Professor, Institute of Clinical Medicine, NCKU
- 2015.8-2017.7 Assistant Professor, Institute of Clinical Medicine, NCKU
- 2007.8-2015.7 Clinical Lecturer/Clinical Assistant Professor, Department of Oncology, National Cheng Kung University Hospital, College of Medicine, NCKU
- 2005.7-2020.9 Attending Physician, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, NCKU
- 1999.7-2005.6 Rotating Intern and Resident, National Taiwan University Hospital, College of Medicine, National Taiwan University
Research Interests
- Medical Oncology
- Anti-Cancer Pharmacology
- DNA repair and Ant-oxidant defense mechanism
- Molecular Chemo-resistance
- Impact of nanoplatform on tumor microenvironment
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Wen-Pin Su is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 15 Finished
-
以多重研究法解開組織缺氧-纖維化循環在胰臟癌之病理機制及發展新穎治療策略-開創抗Hypoxia之胰臟癌新治療—藉由pH-sensitive攜帶Sitravatinib的奈米粒子，以提升PD-1 抗體之療效( II )
Su, W.-P. (PI)
21-08-01 → 22-07-31
Project: Research project
-
開發智慧型奈米---利用葉酸接受器導引並利用Xray 控制釋放之奈米, 如何在胰臟癌發揮治療效果
Su, W.-P. (PI)
21-08-01 → 22-07-31
Project: Research project
-
以多重研究法解開組織缺氧-纖維化循環在胰臟癌之病理機制及發展新穎治療策略-開創抗Hypoxia之胰臟癌新治療—藉由pH-sensitive攜帶Sitravatinib的奈米粒子，以提升PD-1 抗體之療效( I )
Su, W.-P. (PI)
20-08-01 → 21-07-31
Project: Research project
-
開發智慧型奈米---利用葉酸接受器導引並利用Xray 控制釋放之奈米, 如何在胰臟癌發揮治療效果
Su, W.-P. (PI)
20-08-01 → 21-07-31
Project: Research project
-
PD-L1不只是Biomarker！探討肺癌細胞本身的PD-L1促進轉移的機轉，及其與TIP60-mediated 癌症EMT的相關性
Su, W.-P. (PI)
19-08-01 → 20-07-31
Project: Research project
-
Redox disruption using electroactive liposome coated gold nanoparticles for cancer therapy
Chen, Y. C., Chang, L. C., Liu, Y. L., Chang, M. C., Liu, Y. F., Chang, P. Y., Manoharan, D., Wang, W. J., Chen, J. S., Wang, H. C., Chiu, W. T., Li, W. P., Sheu, H. S., Su, W. P. & Yeh, C. S., 2025 Dec, In: Nature communications. 16, 1, 3253.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
Synergistic effect of repurposed mitomycin C in combination with antibiotics against Aeromonas infection: In vitro and in vivo studies
Yeh, C. F., Chen, C. C., Lai, C. C., Liu, J. W., Tang, H. J. & Su, W. P., 2025 Apr, In: Journal of Microbiology, Immunology and Infection. 58, 2, p. 189-197 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance
Wu, C. K., Shiu, J. L., Wu, C. L., Hung, C. F., Ho, Y. C., Chen, Y. T., Tung, S. Y., Yeh, C. F., Shen, C. H., Liaw, H. & Su, W. P., 2024 Jun 10, In: Nucleic acids research. 52, 10, p. 5676-5697 22 p.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
THOR cohort 2 investigators, 2024 Jan, In: Annals of Oncology. 35, 1, p. 107-117 11 p.Research output: Contribution to journal › Article › peer-review
48 Citations (Scopus) -
Harnessing the Power of Sugar-Based Nanoparticles: A Drug-Free Approach to Enhance Immune Checkpoint Inhibition against Glioblastoma and Pancreatic Cancer
Hsu, F. T., Chen, Y. T., Chin, Y. C., Chang, L. C., Chiang, S. C., Yang, L. X., Liu, H. S., Yueh, P. F., Tu, H. L., He, R. Y., Jeng, L. B., Shyu, W. C., Hu, S. H., Chiang, I. T., Liu, Y. C., Chiu, Y. C., Wu, G. C., Yu, C. C., Su, W. P. & Huang, C. C., 2024 Oct 22, In: ACS nano. 18, 42, p. 28764-28781 18 p.Research output: Contribution to journal › Article › peer-review
7 Citations (Scopus)